奥扎格雷联合低分子肝素治疗进展性脑梗死的临床疗效  

Clinical effects of sodium ozagrel combined with low molecular weight heparin on patients with progressive cerebral infarction

作　　者：李红军[1] 陈春富[2] 

机构地区：[1]山东大学附属省立医院医务部,济南250021 [2]山东大学附属省立医院神经内科,济南250021

出　　处：《山东大学学报（医学版）》2011年第5期119-121,124,共4页Journal of Shandong University:Health Sciences

摘　　要：目的观察奥扎格雷钠与低分子肝素联合治疗进展性脑梗死的疗效及安全性。方法随机将急性进展性脑梗死患者112例分为治疗组和对照组各56例。对照组在临床常规治疗的基础上加用奥扎格雷钠80m g,静脉滴注,2次/d,连用14d;治疗组在对照组治疗方案的基础上再加用低分子肝素钠0.4mL皮下注射,2次/d,连用14d;治疗前、后依据美国国立卫生院卒中量表(N IHSS)评分及日常生活能力(B I)评分评定神经功能缺损程度,并监测肝肾功能、血尿常规、凝血4项及心电图。结果与对照组相比,治疗组N IHSS、B I评分在治疗后1、2周时差异具有统计学意义(P<0.05,P<0.01)。血小板、凝血酶原时间均在正常范围内;两组均未见明显不良反应。结论奥扎格雷钠与低分子肝素联合治疗进展性脑梗死疗效较好,使用安全。Objective To observe efficacy and safety of combined sodium ozagrel with low molecular weight heparin on patients with progressive cerebral infarction.Methods 112 cases of progressive cerebral infarction were randomly divided into the treatment group（56 cases） and the control group（56 cases）.The control group was only administered 80 mg of sodium ozagrel,bid,for 14 days.And the treatment group was administered 80 mg of sodium ozagrel,bid,for 14 days and 0.4 mL of low molecular weight heparin sodium injection,bid,for 14 days.The therapeutic effect was evaluated by the National Institutes of Health Stroke Scale（NIHSS） and the Bathal index（BI）.Liver and renal function,blood and urinary routines, blood clotting routine and electrocardiogram（ECG） were detected before and after 14 days of treatment.Results Compared with the control group, grades of NIHSS and BI in the treatment group were significantly lower after one（P〈0.05） and two weeks（P〈0.01）.Both the number of platelets and blood coagulation time were within the normal range. There was no obvious side effect in either groups. Conclusion Sodium ozagrel combined with low molecular weight heparin is an effective and safe therapy for progressive cerebral infarction.

关 键 词：替德肝素 脑梗塞 治疗结果 奥扎格雷钠 

分 类 号：R743.3[医药卫生—神经病学与精神病学]